Global Market Comments
April 25, 2025
Fiat Lux
Featured Trade:
(THE UNITED STATES OF DEBT)
(TLT)
Global Market Comments
April 25, 2025
Fiat Lux
Featured Trade:
(THE UNITED STATES OF DEBT)
(TLT)
The “Exploding National Debt” has been overhanging the markets for as long as I can remember and has had absolutely zero effect. Those who cashed out of markets, sold their homes, and hid everything under their mattress have missed the investment opportunity of the Millennium since 2009.
Why is that?
With ten-year Treasury bond yields grinding up from 0.32% to 4.30% during this period, there is some cause for concern.
The fact is that America has taken advantage of its reserve currency status to become an industrial-strength borrower. The US National Debt now stands at an incredible $37 trillion, up from $10.8 trillion in 2008 when Mad Hedge Fund Trader first published.
The United States is now on the hook for more money than any other country in history. That works out to an eye-popping $108,823 per US citizen.
We are, in fact, have become the United States of Debt. The debt now accounts for 125% of America’s $29.7 trillion GDP, far more than what was seen during the 106% WWII peak. And they were worried then.
What’s worse, over the next decade, the national debt is expected to soar to $50 trillion over the next ten years, assuming that we don’t get into any new wars, where it will become much more.
Former US Secretary of the Treasury Janet Yellen recently confided to me that, “It’s the kind of thing that should keep you awake at night.”
It gets worse.
According to the Federal Reserve Bank of New York, total personal debt topped $17.50 trillion at the end of 2023. An overwhelming share of personal consumption is now funded by credit card borrowing.
Some 33% of Americans now have debts in some form of collection, and that figure reaches an astonishing 50% in many southern states (see map below). Call it the Confederacy of Debt.
Corporations have also been visiting the money trough with increasing frequency. The rating agency Standard & Poor’s has said there could be hard times ahead for corporate America, which, according to the Federal Reserve, is carrying a $13.7 trillion debt load. Company debt has jumped 18.3% since 2020 as companies took advantage of the Fed slashing interest rates in the early days of the COVID-19 pandemic.
The debt-to-capital ratio of the top 1,000 companies has ballooned from 35% to more than 54% and is now the highest in 20 years.
Automobile debt now tops $1.6 trillion and, with lax standards, has become the new subprime market, accounting for 9.2% of all consumer debt.
And remember that other 800-pound gorilla in the room? Student debt has now exceeded $1.77 trillion and is rising, as is the default rate. Provisions in the last tax bill eliminate the deductibility of the interest on student debt, making lives increasingly miserable for young borrowers.
Of course, you can blame the low interest rates that have prevailed for much of the past decade. Who doesn’t want to borrow when the inflation-adjusted long-term cost of money is FREE?
That explains why Apple (AAPL), with $170 billion in cash reserves held overseas, borrowed via ultra-low coupon 30-year bond issues, even though it didn’t need the money. Many other major corporations have done the same.
And while everything looks fine on paper now, what happens if interest rates rise from here?
The Feds will be in dire straits very quickly. Raise short-term rates to the 6% seen at the peak of the last cycle, and the nation’s debt service rockets from 4% seen at the last low to a bone-crushing 10%. That’s when the sushi really hits the fan.
You can expect the same kind of vicious math to strike across the entire spectrum of heavily leveraged borrowers going forward, including you and me.
Rising rates are increasingly shutting first-time buying Millennials out of the housing market, as extortionate 7.10% interest rates prove a formidable barrier.
We are also witnessing the withdrawal of the Chinese as major Treasury bond buyers, who, along with other sovereign buyers, historically took as much as 50% of every issue.
Don’t expect them back until the dollar starts to appreciate again, or until relations between the two countries improve.
Rising supply against fewer buyers sounds like a recipe for much higher interest rates to me.
With these kinds of exponential numbers staring us in the face, why hasn’t financial Armageddon happened already?
I’ll explain.
While at first glance American debt is rising, it has in fact been falling in terms of purchasing power. I’ll use 2022 as an example where the trends are most clear. The National Debt rose by $1.5 trillion. But the inflation rate that year was 9.1%. That means the outstanding debt actually shrank by 9.1%, from $31 trillion to only $28.2 trillion. Compound this over 30 years, the maturity of the longest debt issued by the US Treasury, and how much is the existing national debt?
Zero.
That’s what happened to the Revolutionary War debt, the Civil War Debt, and the debts from WWI and WWII. It all goes to debt Heaven.
Of course, we’ll never get the national debt down to zero because the government keeps increasing spending. Neither American political party wants to own a recession for fear of losing elections. The last one who suffered that fate was George W. Bush, who opened the door for Barack Obama with the Great Financial Crisis. So politicians have learned to spend whatever they must to avoid a similar fate.
You may think that I’ve been smoking California's biggest export to come up with such a hairbrained theory. But there is one person who heartily agrees with me, and that is Mr. Market.
If we really had a debt crisis, stocks and the US dollar would NOT be at all-time highs, the economy would NOT have grown at a robust 3.0%, and inflation this year would NOT be down to only 3.2% against a long-term average of only 4.0%.
No Armageddon here, no debt crisis, nothing to see here.
That’s what Mr. Market thinks anyway, and he is always right.
“Individuals should be buying a little bit of gold every month forever,” said Marc Faber, publisher of the Gloom, Boom, and Doom Report.
When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
Mad Hedge Biotech and Healthcare Letter
April 24, 2025
Fiat Lux
Featured Trade:
(DIVIDEND HUNTING IN BEAR COUNTRY)
(BMY)
One stock in the pharmaceutical sector has been calling to me lately like a siren song amid market turbulence.
I'm talking about Bristol-Myers Squibb Co. (BMY), which has taken a beating in the March-April selloff but is dangling a forward estimated 5% dividend yield while generating a whopping 14% annual free cash flow — tops among the largest drug names.
I've been watching this one since January, when it first dipped below $52. Like a patient fisherman, I've been waiting for just the right moment to cast my line. That moment appears to be now, as BMY slides toward the $50 mark amid broader market jitters and sector rotation. It’s remarkable how often Wall Street throws the proverbial baby out with the bathwater during these periodic fits of selling.
The beauty of BMY is not just valuation. It’s historically proven itself as a financial bomb shelter — outperforming the S&P 500 in four major recessions since 1990.
During the 2020 pandemic, it returned 36% vs. the S&P’s 26%. In the Great Recession, it gained 13% while the broader market fell 16%.
During the 1990 Persian Gulf War recession, it delivered a jaw-dropping 76%.
And here’s one more kicker: BMY’s current 14% free cash flow yield is nearly 10% higher than equivalent cash investment yields — among the best “relative yields” it’s posted in 35 years.
On top of that, its 5%+ dividend towers over the S&P’s 1.3% and Big Pharma’s 3.65% median.
This is a rare setup where both the cash yield and the ability to sustain it align — a combination that’s very hard to beat in a defensive play.
Of course, no stock is bulletproof. BMY will need to navigate patent cliffs and increased regulatory scrutiny on drug pricing.
Wall Street is also pricing in little to no growth in the near term — and that’s probably fair. But the current setup suggests BMY could still outperform, especially if the S&P enters a decline in 2025.
This defensive mindset is why Warren Buffett and other veterans have been moving to abnormally extreme levels of cash since 2024. They're battening down the hatches while the financial seas are still relatively calm.
And speaking of smart investors, I had lunch last week at Tadich Grill with a hedge fund manager I’ve known for decades. When I mentioned I was looking for defensive plays, he immediately brought up BMY.
“What’s rare these days,” he said, “is a company with both a high dividend and the cash flow to actually back it up.” He then showed me his firm’s spreadsheets — stress-tested across recession scenarios back to Nixon — and BMY held firm.
Having run similar models myself (if not quite as colour-coded), I nodded in agreement.
At the current ~$50 share price, BMY’s free cash flow yield stands near 14%. That’s nearly 10% better than risk-free Treasury rates and more than double the Big Pharma peer group median of 6.15%.
So what could go wrong? A steeper summer selloff. Or an aggressive federal move to mandate drug pricing — a risk that’s always on the table, but rarely moves quickly. Supply chain issues, especially for ingredients sourced from China, are also worth watching.
That said, BMY has manufacturing facilities globally, and 71% of its revenue comes from the US. That gives it some insulation if trade tensions flare.
But here’s the thing: those risks hit all major pharma companies. BMY starts from a stronger base: better cash flow, better history, better defensive positioning.
My view? BMY is worth owning for its super-sized dividend and battle-tested resilience. I suggest you buy the dip.
When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
Global Market Comments
April 24, 2025
Fiat Lux
Featured Trade:
(TESTIMONIAL),
(MY FAVORITE PASSIVE/AGGRESSIVE PORTFOLIO)
(ROM), (UYG), (UCC), (DIG), (BIB)
Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.